ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

REGN9533

A development code.

Its studies are mostly in Kidney Failure, Chronic, led by Regeneron Pharmaceuticals.

Furthest: phase 1, since Oct 28, 20242 company-led studies, 1 open or runningNext primary completion: Apr 2, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals21 open or runningphase 1since Oct 28, 2024Oct 28, 2024Apr 2, 2027phase 1 · NCT07759167

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 28, 2024First study: phase 1 study in Healthy VolunteerFirst studyNCT06665828 · 72 enrolled · Belgium
  2. Aug 6, 2026Phase 1 study in Kidney Failure, ChronicNCT07759167 · 36 planned · Belgium

Ahead

  1. Apr 2, 2027Primary completion: phase 1 study in Kidney Failure, ChronicNCT07759167

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07759167Kidney Failure, Chronic · Belgium1RecruitingApr 2, 202736
NCT06665828Healthy Volunteer · Belgium1CompletedJan 29, 202672

How it is read

Names in the registry

  • “REGN9533”, 2 entries

Codes read as this program: REGN9533.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.